Last reviewed · How we verify
NCT05458089
18F-FDG PET/CT in the Diagnosis of Tuberculous Pericarditis
trial testing 18F-FDG in Diagnostic Self Evaluation in 11 participants. Completed in 28 February 2022.
28 February 2022
Quick facts
| Lead sponsor | Wuxi No. 4 People's Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 11 |
| Start date | 1 January 2015 |
| Primary completion | 28 February 2022 |
| Estimated completion | 28 February 2022 |
Drugs / interventions tested
- 18F-FDG — full drug profile →
Conditions studied
- Diagnostic Self Evaluation — all drugs for Diagnostic Self Evaluation →
Sponsor
Wuxi No. 4 People's Hospital
Who can join
Adults 48 to 81, any sex, with Diagnostic Self Evaluation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A total of 11 patients confirmed with tuberculous pericarditis were enrolled in this study to analyze the diagnostic value of 18F-FDG PET/CT for tuberculous pericarditis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05458089
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 18F-FDG
Trials testing the same drug.
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07023861 — The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies · EARLY_PHASE1 · enrolling by invitation
- NCT07023848 — PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors · EARLY_PHASE1 · enrolling by invitation
- NCT06956391 — Ultralow Dose PET Imaging of 18F-FDG Uptake · Phase 2 · recruiting
- NCT06995976 — Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73 · EARLY_PHASE1 · recruiting
Other Wuxi No. 4 People's Hospital trials
Trials by the same sponsor.
- NCT04989010 — Safety Study of 89Zr-Anti-CLDN18.2 mAbs PET Imaging in Patients With CLDN18.2 Positive Solid Tumors · NA · unknown
- NCT04971369 — Safety Study of 89Zr-NY001 PET Imaging in Patients · NA · unknown
- NCT04977128 — 89Zr-labeled KN035 PET Imaging in Patients With PD-L1 Positive Solid Tumors · NA · unknown
- NCT03094897 — Clinic Study of 18F-Al-NOTA-MATBBN in Cancer Diagnostics · EARLY_PHASE1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05458089 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wuxi No. 4 People's Hospital
- Last refreshed: 14 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05458089.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing